Industry: Immune suppressant drugs
MyBregs is an early-stage biopharmaceutical company exploring a new class of immune suppressant drugs that could be used to treat autoimmune and inflammatory disorders.
The company has developed a method for manufacturing induced B-regulatory cells, dubbed iBregs. These iBregs have been shown to cure autoimmune-related brain inflammation in mice.
MyBregs is aiming to turn these therapeutic B-cells into a successful immunotherapy for chronic autoimmune and inflammatory disorders.
Immunosuppressant drugs based on iBregs could also prove valuable for uses such as organ transplants.